AstraZeneca's Imfinzi Approved for Early Gastric Cancer in US
Ticker: AZN · Form: 6-K · Filed: 2025-11-26T00:00:00.000Z
Sentiment: bullish
Topics: drug-approval, oncology, gastric-cancer, fda
TL;DR
FDA greenlights AstraZeneca's Imfinzi for early gastric cancer - big win for patients and the company.
AI Summary
AstraZeneca PLC announced on November 26, 2025, that its drug Imfinzi has received US approval for the treatment of early-stage gastric cancer. This approval marks a significant advancement in treating this specific type of cancer.
Why It Matters
This FDA approval expands treatment options for patients with early-stage gastric cancer, potentially improving outcomes and survival rates for a challenging disease.
Risk Assessment
Risk Level: low — This filing is an announcement of a regulatory approval, which is generally positive news with limited immediate downside risk.
Key Players & Entities
- AstraZeneca PLC (company) — Filer of the report and developer of the drug
- Imfinzi (drug) — The medication that received US approval
- US (country) — Location of the drug approval
- November 2025 (date) — Reporting period for the Form 6-K
- 20251126 (date) — Filing date of the report
FAQ
What specific stage of gastric cancer does the US approval for Imfinzi cover?
The US approval is for early-stage gastric cancer.
Which regulatory body granted the approval for Imfinzi?
The US regulatory body granted the approval, implying the FDA.
What is the filing date of this Form 6-K?
The filing date is 20251126.
What is the primary business of AstraZeneca PLC?
AstraZeneca PLC is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the ticker symbol for AstraZeneca PLC?
The filing does not explicitly state the ticker symbol, but it is a foreign issuer filing a Form 6-K with commission file number 001-11960.
From the Filing
0001654954-25-013450.txt : 20251126 0001654954-25-013450.hdr.sgml : 20251126 20251126062706 ACCESSION NUMBER: 0001654954-25-013450 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251126 FILED AS OF DATE: 20251126 DATE AS OF CHANGE: 20251126 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251523793 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a9865i.htm IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER a9865i FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of November 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________         AstraZeneca PLC   INDEX TO EXHIBITS     1. Imfinzi approved in US for early gastric cancer         26 November 2025   Imfinzi   approved in the US as first and only perioperative immunotherapy for patients with   early gastric and gastroesophageal cancers    Based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% reduction in the risk of death for the Imfinzi regimen vs. chemotherapy alone   AstraZeneca's  Imfinzi  (durvalumab)   in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel)   has been approved in the US for the treatment of adult patients   with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The approved regimen includes neoadjuvant  Imfinzi  in combination with chemotherapy before surgery, followed by adjuvant  Imfinzi  in combination with chemotherapy, then  Imfinzi  monotherapy.   The approval follows   Priority Review   by the Food and Drug Administration (FDA) and is based on event-free survival (EFS) and overall survival (OS) data from the MATTERHORN Phase III trial .   The EFS results were presented during the Plenary Session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in   The New England Journal of Medicine .   O